Do Seon Song, Jeong-Ju Yoo, Jeong Eun Song, Seong Hee Kang, Seung Kak Shin, Seul Ki Han, Sung Won Chung, Gi-Ae Kim, Moon Haeng Hur, Han Ah Lee, Yeonjung Ha, Young Chang, Jae Hyun Yoon, Jae Seung Lee, Sang Gyune Kim, Young Kul Jung, Moon Young Kim
Clin Mol Hepatol 2026;32(3):961-1028. Published online April 28, 2026
Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK” Yang-Hyun Baek Clinical and Molecular Hepatology.2025; 31(1): e123. CrossRef
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Myeongcheol Lee, Hyeon Jin Kim, Yejun Son, Sang Youl Rhee, Lee Smith, Masoud Rahmati, Jiseung Kang, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
Clin Mol Hepatol 2024;30(4):943-958. Published online August 29, 2024
Background/Aims Considering emerging evidence on long COVID, comprehensive analyses of the post-acute complications of SARS-CoV-2 infection in the gastrointestinal and hepatobiliary systems are needed. We aimed to investigate the impact of COVID-19 on the long-term risk of gastrointestinal and hepatobiliary diseases and other digestive abnormalities.
Methods We used three large-scale population-based cohorts: the Korean cohort (discovery cohort), the Japanese cohort (validation cohort-A), and the UK Biobank (validation cohort-B). A total of 10,027,506 Korean, 12,218,680 Japanese, and 468,617 UK patients aged ≥20 years who had SARS-CoV-2 infection between 2020 and 2021 were matched to non-infected controls. Seventeen gastrointestinal and eight hepatobiliary outcomes as well as nine other digestive abnormalities following SARS-CoV-2 infection were identified and compared with controls.
Results The discovery cohort revealed heightened risks of gastrointestinal diseases (HR 1.15; 95% CI 1.08–1.22), hepatobiliary diseases (HR 1.30; 95% CI 1.09–1.55), and other digestive abnormalities (HR 1.05; 95% CI 1.01–1.10) beyond the first 30 days of infection, after exposure-driven propensity score-matching. The risk was pronounced according to the COVID-19 severity. The SARS-CoV-2 vaccination was found to lower the risk of gastrointestinal diseases but did not affect hepatobiliary diseases and other digestive disorders. The results derived from validation cohorts were consistent. The risk profile was most pronounced during the initial 3 months; however, it persisted for >6 months in validation cohorts, but not in the discovery cohort.
Conclusions The incidence of gastrointestinal disease, hepatobiliary disease, and other digestive abnormalities increased in patients with SARS-CoV-2 infection during the post-acute phase.
Citations
Citations to this article as recorded by
Clinical features and inflammatory signatures of patients with persistent gastrointestinal long COVID two years after severe SARS-CoV-2 infection Arlene dos Santos Pinto, Victor Irungu Mwangi, Juliana Costa Ferreira Neves, Alex Bezerra Silva Maciel, Alexandre V. Neto, Jefferson da Silva Valente, Gisely Cardoso de Melo, Wuelton Marcelo Monteiro, Vanderson de Souza Sampaio, Allyson Guimarães da Costa Scientific Reports.2026;[Epub] CrossRef
Long-term effectiveness on glycemic control of insulin compared to combined oral antidiabetic drugs for initial intensive treatment in newly diagnosed type 2 diabetes: A duplicated target trial Tae Hyeon Kim, Yerin Hwang, Selin Woo, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, Dosang Cho, Kyung-Jae Lee, Sang Youl Rhee, Dong Keon Yon Medicine.2026; 105(5): e47235. CrossRef
Overview and Pathophysiology of Long COVID Elisa Perego COVID.2026; 6(3): 53. CrossRef
Postacute sequelae of SARS-CoV-2 infection on ophthalmic diseases: a binational cohort study Jee Myung Yang, Hayeon Lee, Jaeyu Park, Min Kim, Ho-Seok Sa, Joo Yong Lee, Kyung Rim Sung, Francesco Branda, Krishna Prasad Acharya, Dong Keon Yon British Journal of Ophthalmology.2026; : bjo-2025-328412. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks Kui Wang, Ruchen Zhou Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
Association between residential greenness and the risk of inflammatory bowel disease in patients with COVID-19: A Korean nationwide cohort study Dongjin Yeo, Kyeongeun Kim, Juyeong Kim, Sooji Lee, Hayeon Lee, Francesco Branda, Masoud Rahmati, Sunyoung Kim, Ho Geol Woo, Selin Woo, Yerin Hwang, Dong Keon Yon Saudi Journal of Gastroenterology.2026; 32(4): 349. CrossRef
Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK” Yang-Hyun Baek Clinical and Molecular Hepatology.2025; 31(1): e123. CrossRef
Correspondence to editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK” Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon Clinical and Molecular Hepatology.2025; 31(1): e87. CrossRef
Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK” Yang-Hyun Baek Clinical and Molecular Hepatology.2025; 31(1): 319. CrossRef
Artificial intelligence models predicting abnormal uterine bleeding after COVID-19 vaccination Yunjeong Choi, Jaeyu Park, Hyejun Kim, Young Joo Lee, Yongbin Lee, Yong Sung Choi, Seung Geun Yeo, Jiseung Kang, Masoud Rahmati, Hayeon Lee, Dong Keon Yon, Jinseok Lee Scientific Reports.2025;[Epub] CrossRef
COVID-19 and Its Effects on the Hepatobiliary System: A Literature Review Sariya Khan, Jumana Hussain Timraz, Nourah A Al Ghamdi, Nada Y Metwali, Faten A Yaseen, Albatool M Alshaqha, Sarah H Alamri, Heba Turkistani, Anas Dwaima, Ibraheem Ali Algarni Cureus.2025;[Epub] CrossRef
Expression of SARS-CoV-2 entry receptor ACE2 in human brain and its association with Alzheimer’s disease and COVID-19 Sijie Li, Jingyi Sun, He Li, Zhifa Han, Tao Wang, Shan Gao, Ping Zhu, Yan Chen, Peiguang Yan, Mingxin Wang, Guiyou Liu Molecular Psychiatry.2025; 30(7): 3257. CrossRef
Post‐Acute Sequelae of COVID‐19 on Alopecia Areata in Individuals With Mental Illness in South Korea and Japan: A Binational Population‐Based Cohort Study Jaehyeong Cho, Jaeyu Park, Yejun Son, Soeun Kim, Hyesu Jo, Seoyeon Kyung, Hayeon Lee, Dong Keon Yon Journal of Medical Virology.2025;[Epub] CrossRef
Postacute Sequelae of COVID‐19 Across 12 Major Health Domains and 141 Diseases in Individuals With Mental Illness Among COVID‐19 Survivors: A Population‐Based Cohort Study in South Korea Jiseung Kang, Jaeyu Park, Yejun Son, Hyeon Jin Kim, Guillaume Fond, Laurent Boyer, Masoud Rahmati, Hayeon Lee, Dong Keon Yon Journal of Medical Virology.2025;[Epub] CrossRef
Global and Regional Burden of Vaccine‐Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data Jae E. Lee, Hyesu Jo, Hanseul Cho, Jiyeon Oh, Yi Deun Jeong, Sooji Lee, Jaeyu Park, Hyeon Jin Kim, Yejun Son, Soeun Kim, Hayeon Lee, Louis Jacob, Damiano Pizzol, Ho Geol Woo, Jiyoung Hwang, Dong Keon Yon Journal of Medical Virology.2025;[Epub] CrossRef
A Case Definition of a New Disease: A Review of the US Working Definition (USG) and 2024 NASEM Definition for Long COVID Elisa Perego COVID.2025; 5(8): 135. CrossRef
Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study Junyeol Kim, Kyeongmin Lee, Jiyeon Oh, Hayeon Lee, Jong-In Chang, Tae Young Park, Dong Keon Yon, Hyoung-Chul Oh The Korean Journal of Internal Medicine.2025; 40(5): 747. CrossRef
Burden of post-acute sequelae of COVID-19 in patients with type 2 diabetes: a binational cohort study in South Korea and Japan Jiyeon Oh, Soeun Kim, Hyesu Jo, Jaeyu Park, Yejun Son, Sooji Lee, Jinseok Lee, Lee Smith, Jiseung Kang, Junyang Jung, Hayeon Lee, Dong Keon Yon International Journal of Infectious Diseases.2025; 161: 108143. CrossRef
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, Dong Keon Yon Scientific Reports.2024;[Epub] CrossRef
Sex-Specific Trends in the Prevalence of Osteoarthritis and Rheumatoid Arthritis From 2005 to 2021 in South Korea: Nationwide Cross-Sectional Study Seoyoung Park, Yejun Son, Hyeri Lee, Hayeon Lee, Jinseok Lee, Jiseung Kang, Lee Smith, Masoud Rahmati, Elena Dragioti, Mark A Tully, Guillaume Fond, Laurent Boyer, Jun Hyuk Lee, Damiano Pizzol, Jaeyu Park, Selin Woo, Dong Keon Yon JMIR Public Health and Surveillance.2024; 10: e57359. CrossRef
Global Estimates of Vaccine-Associated Hepatic Autoimmune Disorders and Their Related Vaccines, 1968–2024: An International Analysis of the WHO Pharmacovigilance Database Jinyoung Jeong, Hyesu Jo, Jaeyu Park, Lee Smith, Masoud Rahmati, Kwanjoo Lee, Yeonjung Ha, Dong Keon Yon International Archives of Allergy and Immunology.2024; 186(7): 696. CrossRef
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol 2024;30(3):345-359. Published online March 12, 2024
Background/Aims Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV.
Methods This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching.
Results This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the objective response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P<0.001). Despite the superior progression- free survival (PFS) in the lenvatinib group (3.5 vs. 1.8 months, P=0.001), the overall survival (OS, 10.3 vs. 7.5 months, P=0.353) did not differ between the two PS-matched treatment groups.
Conclusions In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.
Citations
Citations to this article as recorded by
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang, Hepatology.2026; 83(5): 1098. CrossRef
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab Hyung-Don Kim, Sun Jin Sym, Hong Jae Chon, Moonho Kim, Jung Hun Kang, Baek-Yeol Ryoo, Choong-kun Lee, Joohyun Hong, Hyewon Ryu, Woo Kyun Bae, Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae-Yong Kim, Changhoon Yoo Journal of Hepatology.2026; 84(2): 308. CrossRef
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Chinatsu Nishioka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Kazuyoshi Ohkawa, Masanori Miyazaki, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Nobuyuk Journal of Gastroenterology.2026; 61(1): 68. CrossRef
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials Sara Ascari, Rusi Chen, Andrea De Sinno, Bernardo Stefanini, Matteo Cescon, Matteo Serenari, Cristina Mosconi, Francesco Tovoli World Journal of Gastroenterology.2026;[Epub] CrossRef
Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach Sun Young Yim, Hayeon Kim, Tae Hyung Kim, Sang-Hee Kang, Youngwoo Lee, Eunho Choi, Yang Jae Yoo, Seong Hee Kang, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kyung Suk Yang, Yitao Tang, Bowha Sohn, Yun Seong Jeong, Hyewon P JHEP Reports.2026; 8(4): 101742. CrossRef
Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy Masatoshi Kudo Liver Cancer.2026; 15(1): 1. CrossRef
Efficacy and Safety of Intensity‐Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second‐Line Treatment for Advanced Hepatocellular Carcinoma: A Real‐World Cohort Study From a Single Center Lingxia Xin, Zhiyu Li, Yirui Zhai, Liming Wang, Feng Ye, Yongkun Sun, Wen Zhang, Tiago Biachi de Castria, Sanjaya K. Satapathy, Vishal G. Shelat, Shaffer R. S. Mok, Jennifer Wu, Shulian Wang, Yueping Liu, Yongwen Song, Yuan Tang, Hao Jing, Hui Fang, Shuna Cancer Medicine.2026;[Epub] CrossRef
Advances in the Management of Hepatocellular Carcinoma: Evolving Systemic Therapy, Perioperative Strategies, and Care for Special Populations Jing He, Xiao-Qin Wu, Zhen-Guang Wang Journal of Clinical Question.2026;[Epub] CrossRef
Current and Emerging Immunotherapy Strategies in Hepatocellular Carcinoma: Standard Treatments and Biomarkers Yoonseok Lee Journal of Digestive Cancer Research.2026; 14(1): 53. CrossRef
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma Chinatsu Nishioka, Yuki Tahata, Kazuki Maesaka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Hisashi Ishida, Takayuki Yakushijin, Sadaharu Iio, Nobuyuki Tatsumi, Kazuho Imanaka, Naruyasu Kaki PLOS One.2026; 21(5): e0341395. CrossRef
Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis Erman Akkus, Christian Hobeika, Julien Edeline, Clémence Hollande, Manon Allaire, Giuliana Amaddeo, Hélène Regnault, Marie Lequoy, Jean Charles Nault, Mohamed Bouattour JHEP Reports.2026; 8(8): 101893. CrossRef
Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Kazunari Tanaka, Kunihiko Tsuji, Ei Itobayashi, Akemi Tsutsui, Koichi Takaguchi, Michitaka Imai, Toru Ishikawa, Takeshi Hatanak Hepatology Research.2026; 56(7): 1161. CrossRef
Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma Piotr T. Wysocki, Paulina Chmiel, Jacek Jassem, Leszek Kraj Current Oncology Reports.2026;[Epub] CrossRef
Five years after IMbrave150 with clinical integration of atezolizumab plus bevacizumab in hepatocellular carcinoma Kuan-Chang Lai, San-Chi Chen Annals of Hepatology.2026; : 102237. CrossRef
Rethinking Progression in Hepatocellular Carcinoma: Is Oligoprogression a Window for Local Ablation? Hisashi Hidaka Hepatology Research.2026; 56(7): 1067. CrossRef
Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis Ronald Blanco Montecino, Nehemias Guevara Rodriguez, Noemy Coreas, Daniel Mendoza-Quispe, Yassine Kilani, Syeda Ashna Fatima Kamal, Kamran Qureshi, John M Richart World Journal of Hepatology.2026;[Epub] CrossRef
Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park Gut and Liver.2026; 20(4): 624. CrossRef
Varices and Hemorrhagic Events during Atezolizumab-bevacizumab Treatment: Reassurance with Caveats for Prognosis Hae Lim Lee Gut and Liver.2026; 20(4): 509. CrossRef
Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Jae-Sung Yoo, Kwon Yong Tak, Hee Sun Cho, Ji Won Han, Jeong Won Jang, Jaejun Lee, Hyun Yang, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Suho Kim, Jung Suk Oh, Ho Jong Chun, Heechul Nam, Pil Soo Sung Radiology.2026;[Epub] CrossRef
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies Hui Li, Junyu Zhou, Xu Zhu Biomedicines.2026; 14(8): 1735. CrossRef
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Bruno Sangro, Josepmaria Argemi, Maxime Ronot, Valerie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter Galle, Laura Dawson, Maria Reig Journal of Hepatology.2025; 82(2): 315. CrossRef
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef
Treatment for hepatocellular carcinoma after immunotherapy Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan Annals of Hepatology.2025; 30(2): 101781. CrossRef
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper, Ulrike Bauer, Christoph Roderburg, Angelo Pirozzi, Najib Ben Khaled, Peter Schr Cancers.2025; 17(6): 972. CrossRef
Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort Najib Ben Khaled, Valentina Zarka, Bernard Hobeika, Julia Schneider, Monika Rau, Alexander Weich, Hans Benno Leicht, Liangtao Ye, Ignazio Piseddu, Michael T. Dill, Arne Kandulski, Matthias Pinter, Ursula Ehmer, Peter Schirmacher, Jens U. Marquardt, Julia Alimentary Pharmacology & Therapeutics.2025; 61(11): 1755. CrossRef
Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma Jingyun Ning, Cao Dai, Qin Liu, Haoming Lin, Rui Zhang British Journal of Surgery.2025;[Epub] CrossRef
Recent advances in polydopamine-coated metal–organic frameworks for cancer therapy Jingchao He, Guangtian Wang, Yongfang Zhou, Bin Li, Pan Shang Frontiers in Bioengineering and Biotechnology.2025;[Epub] CrossRef
Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou Biochemical and Biophysical Research Communications.2025; 778: 152348. CrossRef
PEGylated liposomal metformin overcomes pharmacokinetic barriers to trigger potent mitochondrial disruption and cell cycle arrest in hepatocellular carcinoma Zeinab A. Elzanaty, Medhat W. Shafaa, Seifeldin Elabed, Mohamed M. Omran Scientific Reports.2025;[Epub] CrossRef
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab Jaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, Hyung-Don Kim, Min-Hee Ryu, Kyu-Pyo Kim, Beodeul Kang, Richard S. Finn, Stephen Lam Chan, Changhoon Yoo Liver Cancer.2025; 14(4): 446. CrossRef
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study Pasquale Lombardi, Jung Sun Kim, Giulia F. Manfredi, Ciro Celsa, Claudia A.M. Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Niraj C. Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei-Fan Hsu, JHEP Reports.2025; 7(12): 101595. CrossRef
Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions Yang Gao, Jian-Ping Wang, De-Fei Hong, Chang Yang, Hua Naranmandura Bioengineering.2025; 12(11): 1206. CrossRef
The potential of lenvatinib in breast cancer therapy Yuefeng Shang, Tong Liu, Wenjing Wang Medical Oncology.2024;[Epub] CrossRef
Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity Xiaoyi Zhang, Yachuan Tao, Zhongli Xu, Biao Jiang, Xiaobao Yang, Taomin Huang, Wenfu Tan Biochemical Pharmacology.2024; 230: 116542. CrossRef
Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known? Edoardo G. Giannini Digestive and Liver Disease.2024; 56(12): 2077. CrossRef
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study” Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim Clinical and Molecular Hepatology.2024; 30(4): 1005. CrossRef
Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung Frontiers in Oncology.2024;[Epub] CrossRef
Background/Aims Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
Conclusions Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
Citations
Citations to this article as recorded by
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease Chieh Liu, Yi-Fen Shih, Chun-Jen Liu Clinical and Molecular Hepatology.2026; 32(2): 565. CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Superior accuracy of a novel multidimensional index integrating static and dynamic liver stiffness for hepatocellular carcinoma risk prediction in chronic hepatitis B Yusuke Sano, Naoto Kawabe, Hiroko Sugiyama, Yutaka Sasaki, Keisuke Osakabe, Eizaburo Ohno, Teiji Kuzuya, Senju Hashimoto, Yoshiki Hirooka, Naohiro Ichino Journal of Medical Ultrasonics.2026;[Epub] CrossRef
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno, Keisuke Fukutomi, Kumiko Shirai, Yuki Tahata, Yoshinobu Saito, Akira Nishio, Kunimaro Furuta, Takahi Hepatology Research.2025; 55(1): 22. CrossRef
Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen The Journal of Infectious Diseases.2025; 231(4): 1079. CrossRef
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth Gastroenterology Report.2025;[Epub] CrossRef
Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection Chih-Jan Ko American Journal of Cancer Research.2025; 15(2): 737. CrossRef
Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng Journal of Imaging Informatics in Medicine.2025; 38(6): 4349. CrossRef
The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease Mao-Ping Li, Kai-Zhong Luo Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Chronic hepatitis B: Is it time for expanded antiviral treatment? Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra World Journal of Virology.2025;[Epub] CrossRef
Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon European Radiology.2025; 36(4): 2929. CrossRef
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients Yu-Tong Sun, Qian-Qian Chen World Journal of Hepatology.2024; 16(1): 109. CrossRef
Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis Sixing Shen, Lingyan Pan Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B Danny Con, Steven Tu, Daniel Clayton-Chubb, John S. Lubel, Amanda J. Nicoll, Rohit Sawhney, Stephen Bloom Digestive Diseases and Sciences.2024; 69(4): 1496. CrossRef
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen World Journal of Hepatology.2024; 16(3): 465. CrossRef
Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences Apichat Kaewdech, Pimsiri Sripongpun Siriraj Medical Journal.2024; 76(4): 234. CrossRef
Nonalcoholic fatty liver disease in Sub-Saharan Africa: A descriptive study of the range of histopathological findings in the South-West zone of Nigeria Olusegun Sylvester Ojo, Olusegun Adekanle, Dennis Ndububa, Olawunmi Kolawole, Omolade Adefolabi Betiku Nigerian Journal of Gastroenterology and Hepatology.2024; 16(1): 42. CrossRef
Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation Jun Wang, Hongzhou Lu, Qian Li Frontiers in Immunology.2024;[Epub] CrossRef
Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis Li Zhang, Hong-Di Wu, Yuan-Fang Qian, Hong-Yan Xu World Journal of Clinical Cases.2024; 12(25): 5749. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz Heliyon.2024; 10(18): e37990. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez World Journal of Hepatology.2024; 16(12): 1365. CrossRef
Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation Christopher J Welman, Jacqualine Saunders, Marilyn Zelesco, Steven Abbott, Glenn Boardman, Oyekoya T Ayonrinde Journal of Medical Imaging and Radiation Oncology.2023; 67(1): 45. CrossRef
Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang Digestive Diseases and Sciences.2023; 68(4): 1605. CrossRef
The interplay of long noncoding RNAs and hepatitis B virus Nima Sarfaraz, Srinivas Somarowthu, Michael J. Bouchard Journal of Medical Virology.2023;[Epub] CrossRef
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto Hepatology.2023; 77(5): 1735. CrossRef
Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C Qianwen Zhao, Yunlei Deng Alimentary Pharmacology & Therapeutics.2023; 57(2): 272. CrossRef
The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(2): 189. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao Heliyon.2023; 9(1): e13113. CrossRef
Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu Scientific Reports.2023;[Epub] CrossRef
Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease Pengyan Zhang, Zhenqiu Liu, Hong Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang European Journal of Gastroenterology & Hepatology.2023; 35(3): 294. CrossRef
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen, Xiaomin Yan, Weimao Ding, Qi Zheng, Jie Li, Chao Wu Journal of Viral Hepatitis.2023; 30(4): 287. CrossRef
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease You-Wen Tan, Jia-Min Wang, Xing-Bei Zhou World Journal of Hepatology.2023; 15(2): 237. CrossRef
Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma Ke-Gong Xiong, Tai-Shun Lin, Jin-Feng Kong, Qing-Biao Lin, Li-Fang Chen, Kun-Yu Ke Medicine.2023; 102(9): e33062. CrossRef
Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications Qi Cao, Jia-Bao Zhang, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Xiao-Fei Chen, Dong-Jie Li, Pei Wang Antioxidants & Redox Signaling.2023; 39(7-9): 512. CrossRef
The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy Yang Wang, Jiaxi Li, Shanshan Wang, Yuheng Pang, Pengxiang Liu, Bangxiang Xie, Shuangshuang Dou, Tongwang Yang, Xiaoni Liu, Ying Shi, Dexi Chen Free Radical Biology and Medicine.2023; 204: 326. CrossRef
Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease Stephanos Vassilopoulos, Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Gregorio Benitez, Matthew Kaczynski, Ingrid Lazaridou, Kittichai Promrat, Jack R. Wands, Eleftherios Mylonakis Journal of Viral Hepatitis.2023; 30(8): 685. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince Clinical and Molecular Hepatology.2023; 29(3): 705. CrossRef
The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan Interactive Journal of Medical Research.2023; 12: e40653. CrossRef
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu, Qi Zheng World Journal of Hepatology.2023; 15(8): 964. CrossRef
Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, M auricio Lisker-Melman, David K. Wong, Marc G. Ghany Digestive Diseases and Sciences.2022; 67(2): 676. CrossRef
Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia Madhumita Premkumar, Yogesh K. Chawla Journal of Clinical and Experimental Hepatology.2022; 12(1): 144. CrossRef
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang Liver International.2022; 42(2): 320. CrossRef
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn Alimentary Pharmacology & Therapeutics.2022; 55(1): 97. CrossRef
Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong Frontiers in Oncology.2022;[Epub] CrossRef
Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America Hin Hin Ko, Nishi H. Patel, Sarah Haylock-Jacobs, Karen Doucette, Mang M. Ma, Curtis Cooper, Erin Kelly, Magdy Elkhashab, Edward Tam, Robert Bailey, Alexander Wong, Gerald Minuk, Philip Wong, Scott K. Fung, Giada Sebastiani, Alnoor Ramji, Carla S. Coffin Gastro Hep Advances.2022; 1(1): 106. CrossRef
MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu, Hong Deng Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 673. CrossRef
Validation for models for tumor recurrence after liver transplantation in hepatectomy patients Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh Annals of Surgical Treatment and Research.2022; 102(3): 131. CrossRef
A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu Frontiers in Medicine.2022;[Epub] CrossRef
Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo Journal of Clinical Medicine.2022; 11(6): 1729. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Precision medicine in the era of potent antiviral therapy for chronic hepatitis B Eileen L. Yoon, Dae Won Jun Journal of Gastroenterology and Hepatology.2022; 37(7): 1191. CrossRef
Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai Gut and Liver.2022; 16(3): 456. CrossRef
Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia Ming Yang, Lai Wei Liver International.2022; 42(9): 1981. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li Chinese Medical Journal.2022; 135(14): 1653. CrossRef
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 790. CrossRef
Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases Zhao-Chun Chi World Chinese Journal of Digestology.2022; 30(18): 783. CrossRef
Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B 博诗 陈 Advances in Clinical Medicine.2022; 12(11): 10453. CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee Journal of Korean Medical Science.2022;[Epub] CrossRef
Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease Changtian Su, Qin Yang Frontiers in Pharmacology.2022;[Epub] CrossRef
NAFLD and HBV interplay - related mechanisms underlying liver disease progression Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos Frontiers in Immunology.2022;[Epub] CrossRef
Metabolic syndromes, hepatitis B virus (HBV), and hepatitis C virus as three factors involved in the development of hepatic steatosis: a systematic review and meta-analysis Masoud Keikha, Amirhossein Sahebkar, Tannaz Jamialahmadi, Mohsen Karbalaei Reviews and Research in Medical Microbiology.2022; 33(3): 139. CrossRef
Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies Jonggi Choi, Young‐Suk Lim The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262. CrossRef
HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi Nuclear Medicine and Biology.2021; 96-97: 27. CrossRef
The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho Cancers.2021; 13(10): 2301. CrossRef
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon Hepatology.2021; 73(6): 2266. CrossRef
Pyroptosis: mechanisms and diseases Pian Yu, Xu Zhang, Nian Liu, Ling Tang, Cong Peng, Xiang Chen Signal Transduction and Targeted Therapy.2021;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld JHEP Reports.2021; 3(5): 100350. CrossRef
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2021; 54(9): 1100. CrossRef
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy Rong Fan, Junqi Niu, Hong Ma, Qing Xie, Jun Cheng, Huiying Rao, Xiaoguang Dou, Jianping Xie, Wei Zhao, Jie Peng, Zhiliang Gao, Hongbo Gao, Xinyue Chen, Jinjun Chen, Qiang Li, Hong Tang, Zhengang Zhang, Hong Ren, Mingliang Cheng, Xieer Liang, Chaonan Zhu, Alimentary Pharmacology & Therapeutics.2021; 54(3): 329. CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik Hepatology International.2021; 15(4): 892. CrossRef
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan World Journal of Gastroenterology.2021; 27(26): 3971. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
REPLY: Yun Bin Lee, Juneyoung Lee Hepatology.2021; 74(2): 1135. CrossRef
Reply Hye Won Lee, Beom Kyung Kim Clinical Gastroenterology and Hepatology.2020; 18(1): 264. CrossRef
Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop Houchun H. Hu, Rosa Tamara Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan Magnetic Resonance in Medicine.2020; 83(5): 1565. CrossRef
Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis Miao Fang, Min Yao, Jie Yang, Wen-Jie Zheng, Li Wang, Deng-Fu Yao World Journal of Gastrointestinal Oncology.2020; 12(1): 66. CrossRef
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors? Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan Liver International.2020; 40(3): 496. CrossRef
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim American Journal of Gastroenterology.2020; 115(3): 406. CrossRef
Approach to the patient with chronic hepatitis B and decompensated cirrhosis Mitchell L. Shiffman Liver International.2020; 40(S1): 22. CrossRef
Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up Chong Teik Lim, George Boon Bee Goh, Huihua Li, Tony Kiat-Hon Lim, Wei Qiang Leow, Wei Keat Wan, Rafay Azhar, Wan Cheng Chow, Rajneesh Kumar Microbiology Insights.2020;[Epub] CrossRef
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B Han Ah Lee, Yeon Seok Seo, Seung Up Kim Gastroenterology.2020; 158(8): 2310. CrossRef
Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon Journal of Clinical Gastroenterology.2020; 54(7): 633. CrossRef
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam Microorganisms.2020; 8(10): 1526. CrossRef
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply Han Ah Lee, Seung Up Kim Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094. CrossRef
The Effects of Hepatic Steatosis on the Natural History of HBV Infection Idrees Suliman, Noha Abdelgelil, Farah Kassamali, Tarek I. Hassanein Clinics in Liver Disease.2019; 23(3): 433. CrossRef
First
Prev
